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Serum Concentrations of Symmetric Dimethylarginine and
Creatinine in Dogs with Naturally Occurring Chronic Kidney Disease
J.A. Hall, M. Yerramilli, E. Obare, M. Yerramilli, K. Almes, and D.E. Jewell
Background: Serum concentrations of symmetric dimethylarginine (SDMA) detected chronic kidney disease (CKD) in cats
an average of 17.0 months before serum creatinine (Cr) concentrations increased above the reference interval.
Objectives: To report on the utility of measuring serum SDMA concentrations in dogs for detection of CKD before diag-
nosis by measurement of serum Cr.
Animals: CKD dogs (n = 19) included those persistently azotemic for ≥3 months (n = 5), dogs that were azotemic at the
time of death (n = 4), and nonazotemic dogs (n = 10). CKD dogs were compared with healthy control dogs (n = 20).
Methods: Retrospective study, whereby serum Cr concentrations were determined by enzymatic colorimetry and serum
SDMA concentrations were determined by liquid chromatography-mass spectrometry in dogs with necropsy conﬁrmed CKD.
Results: Serum SDMA increased before serum Cr in 17 of 19 dogs (mean, 9.8 months; range, 2.2–27.0 months). Duration
of elevations in serum SDMA concentrations before the dog developed azotemia (N = 1) or before the dog died (N = 1) was
not determined. Serum SDMA and Cr concentrations were linearly related (r = 0.84; P < .001). Serum SDMA (r = 0.80)
and serum Cr (r = 0.89) concentrations were signiﬁcantly related to glomerular ﬁltration rate (both P < .001).
Conclusion and Clinical Importance: Using serum SDMA as a biomarker for CKD allows earlier detection of kidney dys-
function in dogs than does measurement of serum Cr. Earlier detection might be desirable for initiating renoprotective inter-
ventions that slow progression of kidney disease.
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Chronic kidney disease (CKD) is a common cause ofmorbidity and mortality in dogs. Antemortem
prevalence of CKD varies from 0.9% in dogs of all ages
examined to 2.4% in dogs between 10 and 15 years of
age.1 The prevalence of CKD in dogs in UK veterinary
practices is 0.37%.2
Regardless of the initiating cause, CKD tends to be
progressive.3 Progression occurs because of persistence
of primary disease or addition of other renal insults or
complications. Once glomerular ﬁltration rate (GFR)
has decreased to 30–50% of normal, progression to
end-stage renal failure tends to be inevitable.
Glomerular hyperperfusion leads to glomerulosclerosis
and proteinuria. Compensatory hyperfunctioning renal
tubules progress to tubulointerstitial lesions, destructive
ﬁbrosis, and loss of nephrons. Even in laboratory dogs
maintained under optimal environmental conditions,
the development of renal lesions is progressive over
their lifetime.4 Progressive renal disease is likely present
when renal disease is ﬁrst diagnosed.5 Thus, early recog-
nition of CKD is desirable in order to test for renopro-
tective interventions, such as dietary modiﬁcations that
might slow its progression.6–8
Measurement of GFR is the gold standard method
for estimating renal function and staging kidney dis-
ease.9 In a euhydrated animal with normal ability to
pass urine, GFR is directly related to functional renal
mass. Detecting a decrease in GFR is cumbersome if
done by assessing iohexol clearance because of the
expense and requirement for multiple and accurately
timed blood draws. Therefore, serum creatinine (Cr)
concentration remains the standard surrogate for esti-
mating GFR because it is easily measured and less
expensive.10 However, limitations of using serum Cr as
a biomarker to monitor renal function are that serum
Cr does not increase above the reference range until
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approximately 75% of nephrons are nonfunctioning,11
falsely increased concentrations can occur with some
types of assays,12 and there is secretion of serum Cr
into renal tubules in male dogs.13 Most importantly,
daily production of creatinine is determined largely by
muscle mass, such that lean body mass inﬂuences serum
Cr concentration. Overall, it is less than ideal as an
early biomarker of CKD.9
Symmetric dimethylarginine (SDMA) is produced by
post-translational methylation of arginine residues in
proteins. There are 3 main species of methylated
arginines: monomethylarginine, asymmetric dimethy-
larginine (ADMA), and SDMA.14 Free methylargini-
nes are released into the cytosol after proteolysis and
then enter the blood circulation. Both SDMA and
ADMA are excreted by glomerular ﬁltration and accu-
mulate in patients with renal failure. Symmetric
dimethylarginine is excreted primarily (≥90%) by renal
clearance.15,16 Most of the ADMA is converted to
L-citrulline and dimethylamine by dimethylarginine
dimethylaminohydrolases. Because serum SDMA is not
metabolized by this route, it correlates better with
GFR than ADMA.17 A meta-analysis of 18 studies in
humans showed that serum SDMA concentration is
highly correlated with GFR.17 Serum SDMA also cor-
relates with GFR in cats.18,19 Furthermore, SDMA
concentrations in dogs are not aﬀected by lean body
mass.20
The purpose of this retrospective study was to report
on the utility of measuring serum SDMA concentra-
tions to detect CKD in dogs before diagnosis by single-
point serum Cr measurements. Our goal was to measure
serum SDMA concentrations in dogs before they
became azotemic, provided banked serum samples were
available for measurement, in order to compare serum
SDMA and Cr as biomarkers for early detection of
CKD. The diagnosis of CKD was based on histopathol-
ogy conﬁrmed ﬁndings at necropsy.
Materials and Methods
Animals and Study Design
All study protocols were reviewed and approved by the Institu-
tional Animal Care and Use Committee, Hill’s Pet Nutrition, Inc,
Topeka, KS (Permit Number: CP354). Each dog had an annual
physical examination, CBC, serum biochemical analyses, urinaly-
sis, and urine culture if indicated by the urinalysis results. In addi-
tion, after 2010, serum was frozen at 70°C and banked for
retrospective analyses. Dogs were housed in pairs in indoor runs
or in groups in spacious rooms with natural light that varied with
seasonal changes. All dogs were exercised daily and were provided
with regular opportunities for socialization and environmental
enrichment. All dogs were owned by the commercial funders of
this research or their aﬃliates, who gave permission for them to
be included in this study.
All dogs had been fed many types of commercial and noncom-
mercial foods of varying nutrient compositions, including dry and
canned dog foods, in palatability studies. All foods met the
requirements established by the Association of American Feed
Control Oﬃcials for complete and balanced pet foods for adult
dogs. All dogs had food withheld for 20 hours prior to blood
collection.
Dogs with CKD came from a colony of over 340 Beagles. Dogs
in the colony ranged in age from <1 to 16.7 years, with approxi-
mately 25% of dogs >10 years. Inclusion criteria included
histopathologically conﬁrmed evidence of CKD at necropsy (ﬁbro-
sis, tubular proteinosis, chronic interstitial nephritis, mononuclear
inﬂammatory inﬁltrates, and glomerulosclerosis). Dogs with con-
current disease were included as long as CKD was present at
necropsy. Under veterinary supervision, all dogs had been eutha-
nized when their quality of life deteriorated indicating the need for
euthanasia for humane purposes.
Dogs with CKD (n = 19) included 5 dogs that were persistently
azotemic for ≥3 months (mean, 12 months; range, 4–26 months).
In these persistently azotemic dogs, acute kidney disease might
have been present in some dogs with CKD and gone undiagnosed.
Four additional dogs were azotemic at the time of death. Ten dogs
with elevated serum SDMA were nonazotemic at death. Mean age
of dogs with CKD at the time serum SDMA was ﬁrst detected as
elevated was 12.8 years (range, 6.5–15.8 years). There were 9 ovar-
iohysterectomized females and 10 neutered males. Mean body
weight was 11.7 kg (range, 7.7–14.3 kg).
A similar number of healthy control dogs (N = 20) was selected
from the same colony. These dogs were a cohort of adult dogs
that were fed maintenance food.a All dogs had been immunized
against canine distemper, adenovirus, parvovirus, bordetella, and
rabies, and none had chronic systemic disease on the basis of
results of annual physical examination, complete blood count
determination, serum biochemical analyses, urinalysis, and fecal
examination for parasites. Criteria for inclusion were age >8 years
and requirement of 4 normal GFR tests and 4 normal serum Cr
concentrations over a 6-month period. Urine speciﬁc gravity
(USG) was also assessed at the time of GFR testing. In addition,
these dogs lacked historical, physical, or biochemical evidence of
concurrent disease at the time of inclusion (including no abnormal
ﬁndings on annual urinalysis) and had banked serum samples
available for determination of serum SDMA concentrations. Mean
age of these adult dogs was 10.5 years (range, 8.2–13.3 years).
There were 10 ovariohysterectomized females and 10 neutered
males. Mean body weight was 14.7 kg (range, 8.5–20.8 kg).
Retrospective data were used to document serum Cr concentra-
tions in dogs with CKD. Because serum samples had been banked
as part of annual examinations or as part of protocols for other
studies, exact interval data were not available. Serum SDMA con-
centrations were determined from serum stored in serum banks.
Serum creatinine and SDMA concentrations also were measured
from blood collected prospectively in CKD dogs prior to death.
Analyses
Serum Biomarkers. Serum Cr and blood urea nitrogen (BUN)
concentrations were determined by enzymatic colorimetric meth-
odsb by the in-house laboratory.c
Urinalysis. Urine speciﬁc gravity was determined using a refrac-
tometer. Urine creatinine concentration was used as an internal
reference and measured with the same assay as serum Cr. Urine
protein concentrations were determined using urine supernatant
(benzethonium chloride turbidimetric method).b Urine protein to
creatinine (UPC) ratio calculations are reported as mg/dL protein:
mg/dL creatinine.
Glomerular Filtration Rate. GFR was determined by iohexol
clearance, as previously reported,21 in healthy control dogs at
baseline and at 1.5, 3, and 6 months. In addition, 7 CKD dogs
had GFR determinations performed as part of their medical work
up around the time that serum SDMA increased ≥14 lg/dL. In
brief, a single intravenous injection of iohexol at a dose of 300 mg
I/kg BW was administered and 3 serum samples were collected at
2, 3, and 4 h after iohexol injection. Serum concentrations of
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iohexol were measured by a commercial laboratoryd using an
inductively coupled plasma-atomic emission spectroscopy method.
GFR was estimated from calculations made using a one-compart-
ment model for serum iohexol clearance and normalized according
to body weight in kg.
An empirical correction formula for GFR (Brochner-Mortensen
formula22: Cl = 0.990778 Cl1 – 0.001218 Cl1
2), normalized to
body weight in kg, was applied to GFR values for healthy dogs
and dogs with CKD. It has been shown that in most dogs (exclud-
ing small dogs < 6 kg), GFR estimates predicted by use of the
Brochner-Mortensen formula22,23 are closely related to the esti-
mates predicted by use of a dog-speciﬁc correction formula.24
However, corrected GFR estimates using the Brochner-Mortensen-
formula were 60 to 100% higher in the smallest dogs with the
highest GFR, i.e., one dog was approximately 8 mL/min/kg,
whereas corrected GFR using the dog-speciﬁc formula were ≤ 4
mL/min/kg in all dogs.23 Therefore, we also used an upper thresh-
old of ≤ 4 mL/min/kg in the healthy mature-adult dogs in our
study for GFR values.
Symmetric Dimethylarginine. Serum SDMA concentrations were
determined from banked serum frozen at 70 °C, using liquid
chromatography-mass spectrometry as previously described,20 with
an assay validated in dogs.25 The oldest serum sample used in this
study was dated October 2007. Most SDMA concentrations were
determined prior to or during October 2014. Thus, sample storage
time ranged from 1 week to 7 years. The reference interval for
serum SDMA concentrations in healthy dogs was < 14 lg/dL.e
Necropsy. All CKD dogs had a systematic gross necropsy and
histopathologic evaluation (light microscopy; H&E staining; 4-lm
sections). The underlying cause of death was determined at
necropsy.
Statistical Analysis
Statistical analyses were performed using Statistical Analysis
Software version 9.2.f Data were assessed for normality by the
Shapiro-Wilk test. To investigate the relationships between serum
SDMA and GFR, serum Cr and GFR, and serum SDMA and
serum Cr, correlation coeﬃcients were measured between these
response variables for control and CKD dogs. To accomplish this,
serum SDMA and serum Cr were plotted against GFR data from
both control dogs and CKD dogs (only 7 of 19 CKD dogs had
GFR measurements), and best-ﬁt equations were derived from
data plots. These analyses were performed using repeated-mea-
sures-in-time and the PROC MIXED general linear model in
SAS. Signiﬁcance was accepted as P < .05. Using derived equa-
tions, the GFR that corresponded to the upper limit of the refer-
ence interval for serum SDMA (14 lg/dL)e and serum Cr
(1.4 mg/dL; based on International Renal Interest Society [IRIS]
guidelines for diﬀerentiating Stage 1 from Stage 2 CKD) concen-
trations were calculated.
All healthy dogs had 4 evaluations for serum Cr, BUN, and
SDMA concentrations, USG, and GFR over a 6-month period.
These measurements were used to calculate standard deviation and
coeﬃcient of variation for these variables. The data for serum Cr,
BUN, and SDMA concentrations were not normally distributed.
To achieve normal distribution, we ﬁrst replaced less than 5% of
the highest values with a ceiling value and then log-transformed
the data. The means of the transformed data were then used in
comparisons described below. Raw means, median, and range are
reported. To describe the variability of GFR in healthy control
dogs, mean, range, and percentiles were determined. The lower 2.5
percentile was used to establish the lower limit of normal. Any
dog with GFR consistently below the lower 2.5 percentile was con-
sidered to have abnormal renal function, whereas dogs above this
threshold were considered to have normal renal function.
Healthy dogs were compared with CKD dogs at the time serum
SDMA concentrations were ﬁrst increased (≥14 lg/dL) and at the
time serum Cr concentrations were ﬁrst increased (≥1.4 mg/dL) as
repeated-measures-in-time using the PROC MIXED general linear
model. Comparisons included age; body weight; serum Cr, BUN,
and SDMA concentrations; USG; and GFR measurements. In
addition, the estimated time (in months) that serum SDMA con-
centration was increased before serum Cr concentration was
increased or the dog died was calculated for each dog. Data are
reported as mean (range) unless otherwise indicated. A P < .05
was considered statistically signiﬁcant, and P values are indicated
for all P < .10.
Results
Concurrent serum SDMA and serum Cr concentra-
tions were plotted for CKD dogs and healthy control
dogs (1 time point only) using a scatter plot (Fig 1;
r = 0.84; P < .001). In dogs with CKD, repeated mea-
sures (3 sets of data) within the same animal were
included (ie, at a time when serum SDMA and serum
Cr were both normal, when serum SDMA ﬁrst
increased above normal [≥14 lg/dL], and at the time
when serum Cr was ﬁrst increased above normal
[≥1.4 mg/dL] or at death; Fig 1; Table 1). There were
no situations in which serum SDMA concentration was
within the reference interval and serum Cr concentra-
tion was increased above the reference interval. All
healthy control dogs had serum SDMA and Cr concen-
trations within the reference interval. As CKD dogs
became azotemic, serum SDMA and Cr data points
moved to the upper right quadrant (Fig 1).
Mean (range) of GFR measurements in healthy
mature adult dogs in this study determined from 4
iohexol clearance tests per dog was 4.38 mL/min/kg
(2.33 to 7.08 mL/min/kg). The lower 2.5 percentile,
which was used to establish the lower limit of normal,
was determined to be 2.25 mL/min/kg. All dogs with
GFR 49% decrease below the mean GFR) were consid-
ered to have CKD whereas dogs above this threshold
were considered to have normal renal function. Using
the Brochner-Mortensen formula, mean corrected GFR
(median; range) was 4.32 mL/min/kg (3.93; 2.30-6.95
mL/min/kg). For CKD dogs, mean corrected GFR
(median; range) was 1.36 mL/min/kg (1.43; 0.97-1.62
mL/min/kg). Corrected mean GFR estimates in both
healthy and CKD dogs were within 1% of uncorrected
values. Using an upper threshold of ≤ 4 mL/min/kg in
the healthy mature-adult dogs, mean corrected GFR
(median; range) was 3.68 mL/min/kg (3.93; 2.30 to 4.00
mL/min/kg).
Using serum from data banks to measure SDMA
concentrations, serum SDMA concentrations increased
above the reference interval before serum Cr concentra-
tions increased above the reference interval in 17 of 19
dogs by a mean of 9.8 months (range, 2.2–
27.0 months). A representative example of the relation-
ship between serum SDMA and Cr concentrations
across time is shown for 1 dog in an age versus analytes
concentration bar graph (Fig 2). In 2 of 19 dogs,
although both dogs had increased SDMA concentra-
tions at the time of euthanasia (one dog had SDMA of
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32 lg/dL, sCr was 1.15 mg/dL; the other dog had
SDMA of 16 lg/dL, sCr was 1.66 mg/dL, 5 days prior
sCr was 1.38 mg/dL), we did not have banked serum
samples to determine how long SDMA had been ele-
vated. In 10 of 19 dogs with CKD, serum Cr concentra-
tion did not increase above the reference interval
antemortem (mean serum Cr, 1.11; median, 1.17; range,
0.80–1.38 mg/dL) and the diagnosis of CKD was based
on necropsy ﬁndings of renal disease. In these 10 dogs,
the estimated time that serum SDMA concentration
was increased before serum Cr increased was recorded
as months until death.
The best-ﬁt equation for the relationship between
serum SDMA concentration and GFR was a quadratic
relationship: [GFR in mL/min/kg] = 0.0167 [serum
SDMA concentration in lg/dL]2 – 0.7837 [serum
SDMA concentration in lg/dL] + 9.93 (r = 0.80;
P < .0001). Setting the upper limit of the reference
interval for serum SDMA at 14 lg/dL corresponded to
a GFR of 2.23 mL/min/kg, which represents an approx-
imately 49% decrease from mean GFR of healthy dogs.
The best-ﬁt equation for the relationship between
serum Cr concentration and GFR was a quadratic rela-
tionship: [GFR in mL/min/kg] = 5.32 [serum Cr con-
centration in lg/dL]2 – 15.12 [serum Cr concentration
in lg/dL] + 11.84 (r = 0.89; P < .0001). Setting the
upper limit of the reference interval for serum Cr at
1.4 mg/dL corresponded to a GFR of 1.10 mL/min/kg,
which represents approximately 75% decrease from the
mean GFR of healthy dogs.
In healthy control dogs, the standard deviation and
coeﬃcient of variation for other variables measured
over a 6-month period were serum Cr (0.11 mg/dL;
16.93%), BUN (1.78 mg/dL; 20.42%), serum SDMA
(1.40 lg/dL; 16.06%), and USG (0.01; 1.01%), respec-
tively. Compared with healthy control dogs, dogs with
CKD at the time when serum SDMA was ﬁrst detected
as being ≥14 lg/dL (Table 1) were older (P < .001),
with lower body weight (P < .001), and had higher con-
centrations of serum Cr, BUN, and SDMA (all
P < .001) and lower GFR (P < .001) and USG
(P = .01). The UPC ratios were not measured (no
abnormal ﬁndings on urinalysis) in control dogs for
comparison. Dogs with CKD at the time when serum
Cr was ﬁrst detected as being ≥1.4 mg/dL, or when
dogs died, were older (P < .001), with lower body
weight (P < .001), and continued to have higher serum
Cr, BUN, and SDMA concentrations (all P < .001)
compared with healthy control dogs.
Retrospective IRIS staging of CKD dogs at the time
that serum SDMA concentrations were ﬁrst detected as
elevated (≥14 lg/dL) showed that 17 of 19 dogs were
nonazotemic IRIS stage 1 (serum Cr <1.4 mg/dL) and
2 of 19 dogs were IRIS stage 2 (serum Cr 1.42 and
1.66 mg/dL). Five dogs were nonproteinuric (UPC ratio
≤0.2), 3 were borderline proteinuric (UPC ratio >0.2–
0.5), 7 were proteinuric (UPC ratio >0.5), and 4 were
not assessed. (One of the dogs whose proteinuria was
not assessed when SDMA concentration was ﬁrst
detected as elevated was proteinuric with 0.6 UPC ratio
14 months later, at least 8 months before it became
azotemic.) Blood pressure data were not available. In
the 7 proteinuric dogs in this study, serum SDMA con-
centrations increased above the reference interval either
before serum Cr concentrations increased above the ref-
erence interval or dogs died, by a mean of 6.6 months
(range, 0–13 months). In the 5 nonproteinuric dogs in
this study, serum SDMA concentrations increased
Fig 1. Relationship between serum symmetric dimethylarginine (SDMA; lg/dL) and serum creatinine (Cr; mg/dL) concentrations in 20
healthy dogs (mean age, 10.5 years; range, 8.2–13.3 years; circles) and 19 dogs with chronic renal disease (CKD). CKD dogs are shown at
3 time points: before serum SDMA concentrations were elevated (≥14 lg/dL; mean age, 11.7 years; range, 5.9–15.3 years; diamonds), at
the time serum SDMA concentrations were ﬁrst detected as elevated (mean age, 12.8 years; range, 6.5–15.8 years; squares), and when
serum Cr concentrations were ﬁrst detected as elevated (≥1.4 mg/dL) or at death (mean age, 13.6 years; range, 8.6–16.1 years; triangles).
There is a positive linear relationship between serum SDMA and serum Cr concentrations (r = 0.84; P < .001). No dogs with serum Cr
concentrations above the reference interval (≥1.4 mg/dL) had normal serum SDMA concentrations (<14 lg/dL).
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above the reference interval either before serum Cr con-
centrations increased above the reference interval or
dogs died, by a mean of 10.8 months (range, 4–
27 months; P = .34).
After necropsy and evaluation of gross and micro-
scopic lesions, the reason for euthanasia in 14 dogs was
determined to be CKD. The remaining 5 dogs were
euthanized because of other primary conditions (liver
disease/failure, clinical neurological disease, mammary
carcinoma, and 2 with severe arthritis), but had concur-
rent CKD. Interstitial ﬁbrosis was the most consistent
CKD ﬁnding (n = 17). Lymphoplasmacytic interstitial
nephritis, glomerulosclerosis, and tubular proteinosis
were each reported in 15 dogs. One dog also had micro-
scopic metastatic renal neoplasia (bilateral; carcinoma
of unknown origin). One dog had renal amyloidosis.
Concurrent diseases (of minor clinical signiﬁcance or
clinically undetected) were reported in 9 of the 14 dogs
with CKD as main cause of death: 7 of these dogs had
inﬂammatory bowel disease (IBD), 4 of which also had
hepatic vacuolar degeneration and 2 of which also had
nonrenal neoplasia; and 2 of these 14 dogs had nonre-
nal neoplasia in addition to CKD.
Ten of 19 dogs with CKD diagnosed by necropsy
examination were nonazotemic at the time of death.
Four had concurrent disease listed as underlying cause
of death. In 6 nonazotemic dogs, after evaluation of
gross and microscopic lesions, the reason for euthanasia
was determined by the pathologist to be CKD. Three
dogs had GFR measurements of 1.64, 0.98, and
1.38 mL/min/kg and serum Cr of 1.08, 1.38, and
1.18 mg/dL, respectively. These dogs had interstitial
ﬁbrosis, tubular proteinosis, and mineralization; intersti-
tial ﬁbrosis, interstitial nephritis, and amyloid; and
periglomerular ﬁbrosis, interstitial ﬁbrosis, interstitial
nephritis, glomerulosclerosis, and tubular proteinosis,
respectively. Three more nonazotemic dogs at necropsy
(no GFR available) all had interstitial ﬁbrosis, glomeru-
losclerosis, and tubular proteinosis.
Discussion
Using retrospective serum samples, we were able to
show that serum SDMA increases before serum Cr in
dogs with CKD by a mean of 9.8 months (range, 2.2–
27.0 months). A similar observation has been made in
cats with CKD.18 Because serum samples had been
banked as part of annual examinations or as part of
protocols for other studies, exact interval data were not
available. Conversely, all healthy control dogs had
serum SDMA and Cr concentrations within the refer-
ence interval. Thus, serum SDMA represents a promis-
ing biomarker for early detection of CKD in dogs with
reduced renal function. Early detection is desirable
because it allows testing to determine if dietary or other
renoprotective interventions can slow progression of
CKD, as was shown for cats with IRIS stages 2 and 3
CKD.26
The diagnosis of CKD was made based on histopathol-
ogy conﬁrmed chronic renal lesions at necropsy. The
necropsy ﬁndings were not diagnostic for a speciﬁc kid-
ney disease, but rather a morphologic diagnosis of struc-
Fig 2. Representative dog (neutered male) with serum symmetric dimethylarginine (SDMA; red bars) and serum creatinine (Cr; blue bars)
concentrations indicated across time. Serum SDMA was increased at 8.0 years (15 lg/dL). Glomerular ﬁltration rate was measured at
8.7 years and found to be 1.45 mL/min/kg, which was 67% below the mean of 4.38 mL/min/kg for the healthy control dogs. The dog
became azotemic at 9.9 years (serum Cr, 1.60 mg/dL), approximately 22 months after serum SDMA was increased. The dog died at
10.7 years. Renal histopathology revealed lymphocytic/plasmacytic interstitial nephritis with interstitial and periglomerular ﬁbrosis,
glomerulosclerosis, and tubular proteinosis. The horizontal line represents the upper limit of the reference intervals for serum Cr and
SDMA concentrations.
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tural changes in the kidney, and equivalent to what has
been referred to as chronic interstitial nephritis.27 Thus,
regardless of inciting cause, all dogs had chronic kidney
disease and elevated serum SDMA, but slightly less than
50% were azotemic at the time of death.
A potential limitation of this study is that control dogs
did not have renal biopsies. Each had 4 normal GFR
assessments, and lacked historical, physical, or biochemi-
cal evidence of concurrent renal disease over the 6-month
study period. When assessing renal disease in a mature or
aged animal, normal aging changes can occur in the
absence of any speciﬁc renal insult; these background
changes could lead to decreased renal reserve but usually
not to renal failure.3 In aged dogs, for example renal
weight is reduced by 20–30% because of decreased size
and number of nephrons.3 In humans, GFR decreases
with age because the renal fraction of cardiac output
decreases and because of intrarenal vascular changes
such as coalescence of glomerular capillaries in jux-
tamedullary glomeruli and atrophy of arterioles of corti-
cal glomeruli.3 Glomerular mesangial volume increases,
proximal tubule volume and length decrease, and intersti-
tial connective tissue increases.3 Based on normal serum
SDMA in all control dogs, we can assume that any
purely senescent renal changes quantitatively represented
less than 49% decrease from mean GFR of healthy dogs.
Two reasons exist to explain nonazotemic dogs with
CKD lesions at necropsy. First, as in cats, we have
shown that serum SDMA concentration is an earlier
indicator of reduction in GFR than serum Cr.18 In our
study, the upper reference interval for serum SDMA of
<14 lg/dL corresponded to a GFR of 2.23 mL/min/kg
(approximately 49% decrease from mean), whereas the
upper reference interval for serum Cr of <1.4 mg/dL cor-
responded to a GFR of 1.10 mL/min/kg (approximately
75% decrease from mean). Thus, serum SDMA detects a
reduction in GFR before serum Cr in dogs with CKD on
average 9.8 months earlier. In dogs, we have previously
shown that reduction in lean body mass lowers serum Cr
concentration, but not SDMA concentration.21 In this
study, 6 nonazotemic dogs were euthanized for poor
quality of life that had clinically unrecognized CKD.
Serum SDMA is also a more sensitive biomarker than
serum Cr for assessing renal dysfunction in humans.g,h
Second, not all dogs that had underlying CKD died
from renal failure. Five dogs were euthanized because
of other primary conditions, 4 of which were nona-
zotemic. Concurrent diseases were also reported in 9
dogs where CKD was determined to be the main cause
of death. These included IBD, hepatic vacuolar degen-
eration, and nonrenal neoplasia (neoplasia of the lymph
nodes, urinary bladder, lung, and mammary glands).
Not surprisingly, elevated serum SDMA concentrations
are also found in human patients with multiple disor-
ders compounded by reduced renal function. For exam-
ple, investigators have looked at the association of
serum SDMA concentrations in patients with cardiovas-
cular risk,28–32 with stroke,33 during the acute inﬂamma-
tory response,34 with microvascular dysfunction caused
by critical illness and sepsis,35 with alcoholic liver dis-
ease,36 with hepatorenal syndrome,37 with essential
hypertension,38 with type 2 diabetes with albuminuria,39
and with IBD.40 Serum SDMA was increased in most
patient groups compared with appropriate control
groups. Yet, as previously reviewed,21 researchers con-
cluded that serum SDMA accumulates because of
reduced renal clearance and reﬂects concurrent renal
dysfunction. There is no evidence that elevated serum
SDMA concentrations contribute to lesions or death.41
A signiﬁcant positive correlation (r = 0.84) was present
between serum SDMA and serum Cr concentrations,
similar to what has been reported previously in cats with
CKD.18,42 These results support that serum SDMA is
excreted primarily by the kidneys in both species.
GFR is directly related to functional renal mass.
Early detection of a decrease in GFR might be impor-
tant for initiating dietary or medical interventions in
dogs with CKD when serum Cr concentrations are still
within the reference range (<1.4 mg/dL). In this study,
serum SDMA concentrations were inversely related to
GFR (r = 0.80) and similar to what we have pub-
lished for cats (r = 0.79).18 These results show that
serum SDMA has advantages over serum Cr because it
increases above the reference interval before serum Cr
in dogs with CKD and because serum SDMA concen-
trations are not aﬀected by lean body mass in dogs20 or
cats.19 In support, in Fig 2, the decrease in serum Cr
from 3.1 mg/dL at 10.3 months to 2.44 and 2.27 mg/dL
at 10.6 and 10.7 months is likely the result of decreased
lean body mass, which was not measured in this study,
although total body weight decreased from 15.7 kg to
14.3 and 13.3 kg, respectively. Symmetric dimethy-
larginine was also recently reported in human volun-
teers to provide an accurate and precise estimate of
GFR and to serve as a more sensitive biomarker of
renal dysfunction than serum Cr.g
Mean GFR was higher in healthy control dogs com-
pared with healthy control cats18 (4.38 versus 1.94 mL/
min/kg, respectively) similar to what has been previously
reported,9 and the 2.5 percentile for the reference inter-
val was higher in dogs compared with cats (2.25 versus
1.36 mL/min/kg, respectively). There was also more
variability in GFR values from dogs (range, 2.33–
7.08 mL/min/kg) compared with cats (1.34–3.79 mL/
min/kg).18 This variability was reduced using correction
formulas for GFR, including the Brochner-Mortensen
formula22 and an approximation of the dog-speciﬁc for-
mula23 by setting an upper threshold for GFR. Whether
we used GFR values normalized according to body
weight in kg, or GFR values corrected with the Broch-
ner-Mortensen formula, or with an upper threshold to
approximate the dog-speciﬁc formula, our conclusions
remained the same. No dog with CKD had higher GFR
than any healthy control dog, and serum SDMA (r =
0.80) and serum Cr (r = 0.89) concentrations were
signiﬁcantly correlated to GFR (both P < .001).
The upper limit for the serum SDMA reference interval
(<14 lg/dL) corresponded to a 49% decrease in GFR in
dogs compared with the upper limit for the serum SDMA
reference interval (<14 lg/dL) corresponding to a 24%
decrease in GFR in cats.18 We speculate that more cats
with greater reductions in renal function were included in
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the normal populations used to establish the feline serum
SDMA reference interval (GFR was not measured).i
Also, it is not surprising that the number of months that
serum SDMA was increased before azotemia was
detected was greater in cats compared with dogs, know-
ing that a smaller decrease in GFR from normal is
detected in cats with serum SDMA ≥14 lg/dL.
The use of a biomarker to help identify dogs with
CKD earlier in the disease course might provide addi-
tional options for slowing progressive loss of kidney
function in order to ameliorate clinical and biochemi-
cal consequences of CKD, while maintaining adequate
nutrition.10 Feeding a renal diet to dogs with IRIS
stages 3 and 4 CKD is considered the current standard
of care with strong evidence supporting this recom-
mendation.10 Dietary modiﬁcations include decreased
protein, phosphorus, and sodium content; increased
water soluble vitamins and ﬁber content; increased
caloric density; and additional n-3 fatty acids, antioxi-
dants, and potassium.10 Previous studies in dogs with
a remnant kidney model of CKD have shown that
feeding foods enriched in (n-3) PUFA (15%) reduces
glomerular hypertension, proteinuria, tubulointerstitial
ﬁbrosis, glomerulosclerosis and limits the production
of proinﬂammatory eicosanoid mediators such as
PGE2 and TxA1.
6,7 Studies in 6- to 8-yr-old Beagles
fed dietary (n-3) FA supplements (2.5% dry matter
basis) in combination with antioxidants (vitamin E,
carotenoids, and lutein at concentrations comparable
to those found in commercial canine renal disease
foods) showed independent and additive protective
eﬀects, best explained as causing a decrease in renal
oxidant injury.43 Speciﬁcally, the rate of decline of
GFR was slowed by the use of (n-3) PUFA and by
the addition of dietary antioxidants in this dog rem-
nant model of CKD.43 In another study, obese dogs
fed a high-fat food for 7–9 weeks, or 24 weeks, exhib-
ited increased GFR and renal plasma ﬂow.44
In summary, this study demonstrated the utility of
using serum SDMA as an early indicator of compro-
mised renal function in dogs with CKD. Future studies
are needed to determine if early interventions can
improve the outcome of CKD in dogs.
Footnotes
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e Rentko V, Nabity M, Yerramilli M, et al. Determination of
serum symmetric dimethylarginine reference limit in clinically
healthy dogs. J Vet Intern Med 2013;27:750
f SAS Institute, Cary, NC
g Dixon JJ, Lane K, Dalton RN, et al. Symmetrical dimethy-
larginine is a more sensitive biomarker of renal dysfunction than
creatinine. Crit Care 2013;17:P423
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